GF CSI HK Innovative Drugs Industry ETF(QDII)

Huitianfu Fund Management Co. Reduced ST Pharm to 1.7845 million shares

WuXi Biologics Announces Strong 2025 Financial Forecast, Revenue and Net Profit Both Up

JPMorgan Cuts Stake in Wuxi Biologics by 2.517805 million Shares

China Biopharmaceutical Acquires Herjia for 120 Million

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

BofA Securities Initiates Coverage of CanSino Biologics with a Buy Rating

WuXi Biologics Receives Multiple ESG Ratings and Certifications

CITIC Fund Management Co., Ltd.增持三生制药

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

China Biopharmaceutical Announces Acquisition of Hygieia Biotech

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Sino-pharm Innovation Anticipates Net Loss in 2025 and Increases R&D Investment

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

WuXi AppTec Discloses Business Scale and Global Layout

Guopharma Completes First Delivery of BeiGene's New Product

WuXi AppTec Updates Business Progress at J.P. Morgan Healthcare Conference

WuXi Biologics Announces Latest Progress in GLP-1 Pipeline

WuXi Biologics to issue 584 million new H shares

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

09926

Akeso Inc. reported an 80% objective response rate for ivonescimab plus chemotherapy in a Phase II trial for TNBC. The trial showed a 100% disease control rate and a median progression-free survival of 15.2 months. The safety profile was favorable, with no treatment-related discontinuations or deaths. A Phase III trial is ongoing. Results were presented at the 2025 ESMO IO Congress in London.

Reuters

AKESO

Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial

01801

Innovent Biologics Inc. announced successful Phase 3 trial results for mazdutide, achieving 20.1% weight loss in obese adults. The company plans to submit a new drug application in China soon. Findings have been published in top journals and presented at major conferences.

INNOVENT BIO

Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission

4502

Innovent Biologics and Takeda have finalized a $11.4 billion global strategic collaboration to advance next-generation immuno-oncology and antibody-drug conjugate therapies. The partnership includes co-development and commercialization of IBI363 in the U.S., with Takeda holding exclusive rights outside Greater China. Takeda also gains rights to IBI343 and an option for IBI3001. Innovent receives a $1.2 billion upfront payment, potential milestone payments, and royalties, with shared profits for IBI363 in the U.S.

rttnews

Takeda Pharmaceutical Co. Ltd.

Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies

Akeso Inc. announced that its five innovative drugs have been included in China's 2025 National Reimbursement Drug List, effective January 1, 2026. This inclusion covers major diseases and marks a significant milestone for Akeso, enhancing patient access and supporting its commercialization and global expansion efforts.

Akeso's Five Innovative Drugs Gain Full Inclusion in China's 2025 National Reimbursement Drug List

Innovent Biologics announced promising Phase 1 trial results for IBI3003, a trispecific antibody for relapsed multiple myeloma, at the 2025 ASH Annual Meeting. The trial showed favorable tolerability and encouraging efficacy, especially in high-risk patients. The ongoing Phase 1/2 trial is assessing the drug's safety and efficacy in China and Australia.

Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma

02617

TRANSTHERA-B announced the completion of the first patient dosing in a Phase II clinical trial of the combination therapy of Tiengotine and AKESO's Kintor® and Yida® for advanced hepatocellular carcinoma. The study aims to evaluate the safety and efficacy of the combination therapy, primarily targeting patients with advanced hepatocellular carcinoma who have not received systemic anti-tumor treatment or have failed standard treatment. TRANSTHERA and AKESO have reached a cooperation agreement to jointly develop clinical combination therapies for hepatocellular carcinoma

Zhitong

TRANSTHERA-B

TRANSTHERA-B: The first patient has been dosed in the Phase II clinical trial of the combination of Tiengotine with AKESO's Kantanib® (Cardunili, PD-1/CTLA-4) / Yidafang® (Yivosi, PD-1/VEGF)

Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and a median overall survival of 17.0 months for patients receiving ivonescimab, compared to 14.0 months for those on placebo. The findings indicate consistent benefits across subgroups. Additionally, the HARMONi-A study in China has reached its overall survival clinical endpoint, with results to be shared at future conferences.

Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients

02591

601319

01339

BIDU

09888

The Hang Seng Index opened slightly lower this morning, reporting 26,067 points. The market expects an 86% probability that the Federal Reserve will cut interest rates by 0.25 basis points this week, but analysts indicate that Hong Kong stocks have already priced in the rate cut factors, maintaining narrow fluctuations in the short term. Baidu confirmed plans to spin off Kunlun Core for independent listing, with its stock price rising over 3%. PICC Group's Vice President Yu Ze is suspected of serious disciplinary violations, and the stock price rose by 1.6%. INNOVENT BIO turned "blue" today, with its stock price rising by 1%. In addition, four new stocks have been included in the Hong Kong Stock Connect, with INNOGEN-B rising by 2%

- The U.S. Federal Reserve will hold a two-day meeting starting Tuesday, with an 86% chance of a 0.25% rate cut, impacting global capital flows.  
- Hong Kong stocks are expected to remain in a narrow range between 25,700 and 26,200 points, with the Hang Seng Index opening down 17 points at 26,067.  
- Key developments include Baidu's confirmation of a proposed spin-off and investigation into China People's Insurance Group's vice president, while four new stocks are included in the Hong Kong Stock Connect.

Stheadline

INNOGEN-B

PICC Group

PICC GROUP

Baidu

BIDU-SW

The Hang Seng Index opened slightly lower, Baidu rose another 3%, and INNOGEN-B increased by 2%. Analysis: Beware that the expectations of interest rate cuts have already been reflected. | Hong Kong stock market opens

WXXWY

02269

WuXi Biologics has announced a strategic partnership with the Qatar Free Zones Authority to establish its first integrated CRDMO center in the Middle East. This expansion aims to leverage Qatar's healthcare ecosystem and logistics infrastructure to drive biopharmaceutical innovation and support the growth of Qatar's biotechnology sector.

WuXi Biologics

WUXI BIO

WuXi Biologics Announces First Integrated CRDMO Center in Middle East

Innovent Biologics Inc. has received approval from China's NMPA for PECONDLE® to treat moderate-to-severe plaque psoriasis, marking it as the first domestically developed IL-23p19 inhibitor in China. The approval was based on positive Phase 3 study results.

Innovent Biologics Wins China Approval for PECONDLE to Treat Plaque Psoriasis

CMB International maintains a "Buy" rating on AKESO, with a target price of HKD 183. The bank predicts that the overseas peak sales of Aito will reach USD 16.5 billion. The latest HARMONi research data shows that the survival benefit of Aito has improved, with OSHR improving to 0.78 and PFSHR at 0.57. Although uncertainties regarding approval still exist, the likelihood of approval in the United States has increased

China Merchants Jinling International: Maintains AKESO "Buy" Rating with a Target Price of HKD 183

Akeso Inc. announced promising results from a Phase Ib/II clinical study of cadonilimab and pulocimab for immunotherapy-resistant non-small cell lung cancer (NSCLC) at the 2025 World Conference on Lung Cancer. In the squamous NSCLC subgroup, median overall survival was 16.7 months, while in the non-squamous subgroup, it was 12.8 months. The combination therapy shows potential for addressing unmet needs in IO-resistant lung cancer, with plans for a Phase III study. Akeso's ivonescimab has also shown efficacy in this population, with a Phase III trial initiated.

Akeso Inc. Announces Promising Results from Phase Ib/II Clinical Study of Cadonilimab and Pulocimab Combination Therapy in IO-Resistant NSCLC at 2025 WCLC

Huayuan Securities maintains a "Buy" rating on AKESO, expecting operating revenues of 3.419 billion, 5.598 billion, and 8.577 billion yuan for 2025-2027, respectively. The company achieved revenue of 1.412 billion yuan in the first half of 2025, a year-on-year increase of 37.75%, with a net profit attributable to the parent company of -570 million yuan. The updated overseas data for the monoclonal antibody Yosprala HARMONi shows further improvement in overall survival (OS), with steady growth in commercialization. Subsequent product approvals are expected to bring incremental performance. The reasonable equity value is HKD 187.5 billion

HuaYuan Securities: AKESO HARMONi data further updated, maintaining a "Buy" rating

Akeso Inc. has launched a global Phase II trial named COMPASSION-36/AK104-225 to evaluate the efficacy of cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab and bevacizumab. This trial is the first global registrational study of cadonilimab, taking place in China, the U.S., and Europe, aiming to provide second-line treatment options for advanced HCC. Results are pending.

Akeso Inc. Initiates Global Phase II Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Hong Kong stocks rose for the third consecutive session, gaining 83 points to reach 25,974. The rise was driven by improved sentiment from Wall Street, expectations of a Fed rate cut, and strong performance in property and financial stocks. Gains were supported by mainland market momentum and strong trade data, though tempered by caution ahead of China's industrial profit data. Pharma stocks like Akeo Inc. and Innovent Biologics outperformed.

GF CSI HK Innovative Drugs Industry ETF(QDII)(513120.SH)

Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial

Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission

Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies

Akeso's Five Innovative Drugs Gain Full Inclusion in China's 2025 National Reimbursement Drug List

Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma